Survivors Remorse: antibody-mediated protection against HIV-1

Immunological Reviews

Volumn 275, Issue 1, 2017, Pages 271-284

  Lewis, George K ^a   Pazgier, Marzena ^a   DeVico, Anthony L ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS vaccine; HIV 1; neutralizing antibodies; non neutralizing antibodies

Indexed keywords

ANTIBODY; EPITOPE; NEUTRALIZING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN RECOGNITION; CLINICAL TRIAL (TOPIC); HIV SURVIVOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PASSIVE IMMUNIZATION; PRIMATE; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS TRANSMISSION; ANIMAL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE EVASION; IMMUNOLOGY;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; CLINICAL TRIALS AS TOPIC; EPITOPES; HIV ANTIBODIES; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE EVASION; PRIMATES;

EID: 85010910592     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12510     Document Type: Review

References (200)

1. Robert-Guroff M, Brown M, Gallo RC. HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature. 1985;316:72–74.
2. Robert-Guroff M, Reitz MS Jr, Robey WG, Gallo RC. In vitro generation of an HTLV-III variant by neutralizing antibody. J Immunol. 1986;137:3306–3309.
3. Matsushita S, Robert-Guroff M, Rusche J, et al. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J Virol. 1988;62:2107–2114.
4. Palker TJ, Clark ME, Langlois AJ, et al. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci USA. 1988;85:1932–1936.
5. Rusche JR, Javaherian K, McDanal C, et al. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci USA. 1988;85:3198–3202.
6. Skinner MA, Langlois AJ, McDanal CB, McDougal JS, Bolognesi DP, Matthews TJ. Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. J Virol. 1988;62:4195–4200.
7. Javaherian K, Langlois AJ, McDanal C, et al. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci USA. 1989;86:6768–6772.
8. Haynes BF, Shaw GM, Korber B, et al. HIV-host interactions: Implications for vaccine design. Cell Host Microbe. 2016;19:292–303.
9. Burton DR, Hangartner L. Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu Rev Immunol. 2016;34:635–659.
10. Burton DR, Mascola JR. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol. 2015;16:571–576.
11. Lewis GK. Role of Fc-mediated antibody function in protective immunity against HIV-1. Immunology. 2014;142:46–57.
12. Cocklin SL, Schmitz JE. The role of Fc receptors in HIV infection and vaccine efficacy. Curr Opin HIV AIDS. 2014;9:257–262.
13. Carias AM, Hope TJ. Phagocytosis: Cell biology view of antiviral function. Curr Opin HIV AIDS. 2014;9:271–277.
14. Forthal D, Hope TJ, Alter G. New paradigms for functional HIV-specific nonneutralizing antibodies. Curr Opin HIV AIDS. 2013;8:392–400.
15. Pollara J, Bonsignori M, Moody MA, Pazgier M, Haynes BF, Ferrari G. Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses. Curr HIV Res. 2013;11:378–387.
16. Veillette M, Richard J, Pazgier M, Lewis GK, Parsons MS, Finzi A. Role of HIV-1 envelope glycoproteins conformation and accessory proteins on ADCC responses. Curr HIV Res. 2016;14:9–23.
17. + T cells. Nat Med. 2003;9:727–728.
18. Crooks AM, Bateson R, Cope AB, et al. Precise quantitation of the latent HIV-1 reservoir: Implications for eradication strategies. J Infect Dis. 2015;212:1361–1365.
19. Foresman L, Jia F, Li Z, et al. Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques. AIDS Res Hum Retroviruses. 1998;14:1035–1043.
20. Joag SV, Li Z, Wang C, et al. Passively administered neutralizing serum that protected macaques against infection with parenterally inoculated pathogenic simian-human immunodeficiency virus failed to protect against mucosally inoculated virus. AIDS Res Hum Retroviruses. 1999;15:391–394.
21. Mascola JR, Lewis MG, Stiegler G, et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol. 1999;73:4009–4018.
22. Shibata R, Igarashi T, Haigwood N, et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys [see comment]. Nat Med. 1999;5:204–210.
23. Baba TW, Liska V, Hofmann-Lehmann R, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med. 2000;6:200–206.
24. Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 2000;6:207–210.
25. Hofmann-Lehmann R, Rasmussen RA, Vlasak J, et al. Passive immunization against oral AIDS virus transmission: An approach to prevent mother-to-infant HIV-1 transmission? J Med Primatol. 2001;30:190–196.
26. Parren PWHI, Marx PA, Hessell AJ, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol. 2001;75:8340–8347.
27. Nishimura Y, Igarashi T, Haigwood N, et al. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J Virol. 2002;76:2123–2130.
28. Nishimura Y, Igarashi T, Haigwood NL, et al. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: Implications for HIV-1 vaccine development. Proc Natl Acad Sci USA. 2003;100:15131–15136.
29. Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 2007;449:101–104.
30. Hessell AJ, Poignard P, Hunter M, et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med. 2009;15:951–954.
31. Hessell AJ, Rakasz EG, Poignard P, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009;5:e1000433.
32. Hessell AJ, Rakasz EG, Tehrani DM, et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol. 2010;84:1302–1313.
33. Burton DR, Hessell AJ, Keele BF, et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci USA. 2011;108:11181–11186.
34. Moldt B, Rakasz EG, Schultz N, et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci USA. 2012;109:18921–18925.
35. Moldt B, Shibata-Koyama M, Rakasz EG, et al. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol. 2012;86:6189–6196.
36. Klein K, Veazey RS, Warrier R, et al. Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge. J Virol. 2013;87:11604–11616.
37. Moog C, Dereuddre-Bosquet N, Teillaud JL, et al. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal Immunol. 2014;7:46–56.
38. Pegu A, Yang ZY, Boyington JC, et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med. 2014;6:243ra288.
39. Shingai M, Donau OK, Plishka RJ, et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J Exp Med. 2014;211:2061–2074.
40. Saunders KO, Pegu A, Georgiev IS, et al. Sustained delivery of a broadly neutralizing antibody in nonhuman primates confers long-term protection against simian/human immunodeficiency virus infection. J Virol. 2015;89:5895–5903.
41. Saunders KO, Wang L, Joyce MG, et al. Broadly neutralizing human immunodeficiency virus type 1 antibody gene transfer protects non-human primates from mucosal simian-human immunodeficiency virus infection. J Virol. 2015;89:8334–8345.
42. Joseph SB, Swanstrom R. HIV/AIDS. A fitness bottleneck in HIV-1 transmission. Science. 2014;345:136–137.
43. Shaw GM, Hunter E. HIV transmission. Cold Spring Harb Perspect Med. 2012;2:1–23.
44. Derdeyn CA, Hunter E. Viral characteristics of transmitted HIV. Curr Opin HIV AIDS. 2008;3:16–21.
45. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA. 2008;105:7552–7557.
46. Abrahams MR, Anderson JA, Giorgi EE, et al. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol. 2009;83:3556–3567.
47. Salazar-Gonzalez JF, Salazar MG, Keele BF, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med. 2009;206:1273–1289.
48. Bar KJ, Li H, Chamberland A, et al. Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol. 2010;84:6241–6247.
49. Li H, Bar KJ, Wang S, et al. High multiplicity infection by HIV-1 in men who have sex with men. PLoS Pathog. 2010;6:e1000890.
50. Stone M, Keele BF, Ma ZM, et al. A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251. J Virol. 2010;84:7083–7095.
51. Lee HY, Giorgi EE, Keele BF, et al. Modeling sequence evolution in acute HIV-1 infection. J Theor Biol. 2009;261:341–360.
52. Asmal M, Hellmann I, Liu W, et al. A signature in HIV-1 envelope leader peptide associated with transition from acute to chronic infection impacts envelope processing and infectivity. PLoS ONE. 2011;6:e23673.
53. Gnanakaran S, Bhattacharya T, Daniels M, et al. Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog. 2011;7:e1002209.
54. Wilen CB, Parrish NF, Pfaff JM, et al. Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J Virol. 2011;85:8514–8527.
55. Baalwa J, Wang S, Parrish NF, et al. Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology. 2013;436:33–48.
56. Parrish NF, Gao F, Li H, et al. Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci USA. 2013;110:6626–6633.
57. Gonzalez MW, DeVico AL, Lewis GK, Spouge JL. Conserved molecular signatures in gp120 are associated with the genetic bottleneck during SIV, SHIV, and HIV-1 transmission. J Virol. 2015;89:3619–3629.
58. Ochsenbauer C, Edmonds TG, Ding H, et al. Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol. 2012;86:2715–2728.
59. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA. 2003;100:4144–4149.
60. Derdeyn CA, Decker JM, Bibollet-Ruche F, et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science. 2004;303:2019–2022.
61. Chohan B, Lang D, Sagar M, et al. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol. 2005;79:6528–6531.
62. Roederer M, Keele BF, Schmidt SD, et al. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature. 2014;505:502–508.
63. Lee FH, Mason R, Welles H, et al. Breakthrough virus neutralization resistance as a correlate of protection in a nonhuman primate heterologous simian immunodeficiency virus vaccine challenge study. J Virol. 2015;89:12388–12400.
64. Burton SL, Kilgore KM, Smith SA, et al. Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses. Proc Natl Acad Sci USA. 2015;112:10780–10785.
65. Smith SA, Kilgore KM, Kasturi SP, et al. Signatures in simian immunodeficiency virus SIVsmE660 envelope gp120 are associated with mucosal transmission but not vaccination breakthrough in rhesus macaques. J Virol. 2016;90:1880–1887.
66. Seaman MS, Leblanc DF, Grandpre LE, et al. Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens. Virology. 2007;367:175–186.
67. Seaman MS, Janes H, Hawkins N, et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol. 2010;84:1439–1452.
68. Munro JB, Gorman J, Ma X, et al. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. Science. 2014;346:759–763.
69. Pancera M, Zhou T, Druz A, et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature. 2014;514:455–461.
70. Guttman M, Cupo A, Julien JP, et al. Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env. Nat Commun. 2015;6:6144.
71. Munro JB, Mothes W. Structure and dynamics of the native HIV-1 Env trimer. J Virol. 2015;89:5752–5755.
72. Liao HX, Lynch R, Zhou T, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature. 2013;496:469–476.
73. Doria-Rose NA, Schramm CA, Gorman J, et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014;509:55–62.
74. Bonsignori M, Hwang KK, Chen X, et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol. 2011;85:9998–10009.
75. Wu X, Zhou T, Zhu J, et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science. 2011;333:1593–1602.
76. Lynch RM, Tran L, Louder MK, et al. The development of CD4 binding site antibodies during HIV-1 infection. J Virol. 2012;86:7588–7595.
77. Wu X, Wang C, O'Dell S, et al. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. J Virol. 2012;86:5844–5856.
78. Wibmer CK, Bhiman JN, Gray ES, et al. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog. 2013;9:e1003738.
79. Bonsignori M, Zhou T, Sheng Z, et al. Maturation pathway from germline to broad HIV-1 neutralizer of a CD4-mimic antibody. Cell. 2016;165:449–463.
80. MacLeod DT, Choi NM, Briney B, et al. Early antibody lineage diversification and independent limb maturation lead to broad HIV-1 neutralization targeting the Env high-mannose patch. Immunity. 2016;44:1215–1226.
81. Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell. 2014;158:1243–1253.
82. Narayan O, Griffin DE, Clements JE. Virus mutation during ‘slow infection’: Temporal development and characterization of mutants of visna virus recovered from sheep. J Gen Virol. 1978;41:343–352.
83. Salinovich O, Payne SL, Montelaro RC, Hussain KA, Issel CJ, Schnorr KL. Rapid emergence of novel antigenic and genetic variants of equine infectious anemia virus during persistent infection. J Virol. 1986;57:71–80.
84. Crooks ET, Tong T, Chakrabarti B, et al. Vaccine-elicited tier 2 HIV-1 neutralizing antibodies bind to quaternary epitopes involving glycan-deficient patches proximal to the CD4 binding site. PLoS Pathog. 2015;11:e1004932.
85. Derking R, Ozorowski G, Sliepen K, et al. Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer. PLoS Pathog. 2015;11:e1004767.
86. Pritchard LK, Vasiljevic S, Ozorowski G, et al. Structural constraints determine the glycosylation of HIV-1 envelope trimers. Cell Rep. 2015;11:1604–1613.
87. Behrens AJ, Vasiljevic S, Pritchard LK, et al. Composition and antigenic effects of individual glycan sites of a trimeric HIV-1 envelope glycoprotein. Cell Rep. 2016;14:2695–2706.
88. Stewart-Jones GB, Soto C, Lemmin T, et al. Trimeric HIV-1-Env structures define glycan shields from clades A, B, and G. Cell. 2016;165:813–826.
89. McCoy LE, van Gils MJ, Ozorowski G, et al. Holes in the glycan shield of the native HIV envelope are a target of trimer-elicited neutralizing antibodies. Cell Rep. 2016;16:2327–2338.
90. Chaillon A, Braibant M, Hue S, et al. Human immunodeficiency virus type-1 (HIV-1) continues to evolve in presence of broadly neutralizing antibodies more than ten years after infection. PLoS ONE. 2012;7:e44163.
91. Bouvin-Pley M, Morgand M, Meyer L, et al. Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: A comprehensive study using the most potent and broadly neutralizing monoclonal antibodies. J Virol. 2014;88:13910–13917.
92. Freund NT, Horwitz JA, Nogueira L, et al. A new glycan-dependent CD4-binding site neutralizing antibody exerts pressure on HIV-1 in vivo. PLoS Pathog. 2015;11:e1005238.
93. Krumm SA, Mohammed H, Le KM, et al. Mechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodies. Retrovirology. 2016;13:8.
94. Mangel M, Samaniego FJ. Abraham Wald's work on aircraft survivability. J Am Stat Assoc. 1984;79:259–267.
95. Smith G. Standard Deviations, Flawed Assumptions, Tortured Data, and Other Ways to Lie with Statistics (1st edn). New York, NY: Overlook Press; 2014.
96. Wolfowitz J. Abraham Wald, 1902-1950. Ann Math Stat. 1952:1–13.
97. Diskin R, Klein F, Horwitz JA, et al. Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. J Exp Med. 2013;210:1235–1249.
98. Starcich BR, Hahn BH, Shaw GM, et al. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell. 1986;45:637–648.
99. Gaschen B, Taylor J, Yusim K, et al. Diversity considerations in HIV-1 vaccine selection. Science. 2002;296:2354–2360.
100. Zhou T, Georgiev I, Wu X, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science. 2010;329:811–817.
101. Wu X, Yang ZY, Li Y, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010;329:856–861.
102. Pejchal R, Walker LM, Stanfield RL, et al. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci USA. 2010;107:11483–11488.
103. Walker LM, Phogat SK, Chan-Hui PY, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009;326:285–289.
104. Garces F, Lee JH, de Val N, et al. Affinity maturation of a potent family of HIV antibodies is primarily focused on accommodating or avoiding glycans. Immunity. 2015;43:1053–1063.
105. Purtscher M, Trkola A, Gruber G, et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 1994;10:1651–1658.
106. Falkowska E, Le KM, Ramos A, et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity. 2014;40:657–668.
107. Del Prete GQ, Ailers B, Moldt B, et al. Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins. Cell Host Microbe. 2014;16:412–418.
108. Cuevas JM, Geller R, Garijo R, Lopez-Aldeguer J, Sanjuan R. Extremely high mutation rate of HIV-1 in vivo. PLoS Biol. 2015;13:e1002251.
109. Geller R, Domingo-Calap P, Cuevas JM, Rossolillo P, Negroni M, Sanjuan R. The external domains of the HIV-1 envelope are a mutational cold spot. Nat Commun. 2015;6:8571.
110. Sanjuan R, Domingo-Calap P. Mechanisms of viral mutation. Cell Mol Life Sci. 2016;73:4433–4448.
111. Sarzotti-Kelsoe M, Daniell X, Todd CA, et al. Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells. J Immunol Methods. 2014;409:147–160.
112. Desrosiers RC, Wyand MS, Kodama T, et al. Vaccine protection against simian immunodeficiency virus infection. Proc Natl Acad Sci USA. 1989;86:6353–6357.
113. Murphey-Corb M, Martin LN, Davison-Fairburn B, et al. A formalin-inactivated whole SIV vaccine confers protection in macaques. Science. 1989;246:1293–1297.
114. Henderson LE, Sowder R, Copeland TD, et al. Direct identification of class II histocompatibility DR proteins in preparations of human T-cell lymphotropic virus type III. J Virol. 1987;61:629–632.
115. Arthur LO, Bess JW Jr, Sowder RC 2nd, et al. Cellular proteins bound to immunodeficiency viruses: Implications for pathogenesis and vaccines. Science. 1992;258:1935–1938.
116. Mills KH, Page M, Chan WL, et al. Protection against SIV infection in macaques by immunization with inactivated virus from the BK28 molecular clone, but not with BK28-derived recombinant env and gag proteins. J Med Primatol. 1992;21:50–58.
117. Chan WL, Rodgers A, Grief C, et al. Immunization with class I human histocompatibility leukocyte antigen can protect macaques against challenge infection with SIVmac-32H. AIDS. 1995;9:223–228.
118. Yang GB, Wang Y, Babaahmady K, et al. Immunization with recombinant macaque major histocompatibility complex class I and II and human immunodeficiency virus gp140 inhibits simian-human immunodeficiency virus infection in macaques. J Gen Virol. 2012;93:1506–1518.
119. Leith JG, Clark DA, Matthews TJ, et al. Assessing human alloimmunization as a strategy for inducing HIV type 1 neutralizing anti-HLA responses. AIDS Res Hum Retroviruses. 2003;19:957–965.
120. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002;46:1896–1905.
121. Melikyan GB. Common principles and intermediates of viral protein-mediated fusion: The HIV-1 paradigm. Retrovirology. 2008;5:111.
122. Page M, Quartey-Papafio R, Robinson M, et al. Complement-mediated virus infectivity neutralisation by HLA antibodies is associated with sterilising immunity to SIV challenge in the macaque model for HIV/AIDS. PLoS ONE. 2014;9:e88735.
123. Spear GT, Sullivan BL, Landay AL, Lint TF. Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis. J Virol. 1990;64:5869–5873.
124. Nakamura M, Sasaki H, Terada M, Ohno T. Complement-dependent virolysis of HIV-1 with monoclonal antibody NM-01. AIDS Res Hum Retroviruses. 1993;9:619–626.
125. Spear GT, Takefman DM, Sullivan BL, Landay AL, Jennings MB, Carlson JR. Anti-cellular antibodies in sera from vaccinated macaques can induce complement-mediated virolysis of human immunodeficiency virus and simian immunodeficiency virus. Virology. 1993;195:475–480.
126. Aasa-Chapman MM, Holuigue S, Aubin K, et al. Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. J Virol. 2005;79:2823–2830.
127. Zhao J, Pinczewski J, Gomez-Roman VR, et al. Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen. J Virol. 2003;77:8354–8365.
128. Patterson LJ, Malkevitch N, Venzon D, et al. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol. 2004;78:2212–2221.
129. Gomez-Roman VR, Florese RH, Peng B, et al. An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. J Acquir Immune Defic Syndr. 2006;43:270–277.
130. + T cell responses. Virology. 2006;353:83–98.
131. Demberg T, Florese RH, Heath MJ, et al. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol. 2007;81:3414–3427.
132. DeVico A, Fouts T, Lewis GK, et al. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc Natl Acad Sci USA. 2007;104:17477–17482.
133. Barouch DH, Liu J, Lynch DM, et al. Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys. J Virol. 2009;83:9584–9590.
134. Florese RH, Demberg T, Xiao P, et al. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with tat/env compared with multigenic vaccines. J Immunol. 2009;182:3718–3727.
135. Hidajat R, Xiao P, Zhou Q, et al. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol. 2009;83:791–801.
136. Barouch DH, Liu J, Li H, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 2012;482:89–93.
137. Xiao P, Patterson LJ, Kuate S, et al. Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge. J Virol. 2012;86:4644–4657.
138. Demberg T, Brocca-Cofano E, Kuate S, et al. Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques. Virology. 2013;440:210–221.
139. Thomas MA, Tuero I, Demberg T, et al. HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques. Virology. 2014;471-473C:81–92.
140. Barouch DH, Alter G, Broge T, et al. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science. 2015;349:320–324.
141. Fouts TR, Bagley K, Prado IJ, et al. Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. Proc Natl Acad Sci USA. 2015;112:992–999.
142. Bomsel M, Tudor D, Drillet AS, et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity. 2011;34:269–280.
143. Smith AJ, Wietgrefe SW, Shang L, et al. Live simian immunodeficiency virus vaccine correlate of protection: Immune complex-inhibitory Fc receptor interactions that reduce target cell availability. J Immunol. 2014;193:3126–3133.
144. Li Q, Zeng M, Duan L, et al. Live simian immunodeficiency virus vaccine correlate of protection: Local antibody production and concentration on the path of virus entry. J Immunol. 2014;193:3113–3125.
145. Pilcher CD, Joaki G, Hoffman IF, et al. Amplified transmission of HIV-1: Comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS. 2007;21:1723–1730.
146. Patel P, Borkowf CB, Brooks JT, Lasry A, Lansky A, Mermin J. Estimating per-act HIV transmission risk: A systematic review. AIDS. 2014;28:1509–1519.
147. Regoes RR, Longini IM, Feinberg MB, Staprans SI. Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges. PLoS Med. 2005;2:e249.
148. Keele BF, Li H, Learn GH, et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med. 2009;206:1117–1134.
149. Bogers WM, Davis D, Baak I, et al. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology. 2008;382:217–225.
150. Rogers KA, Jayashankar L, Scinicariello F, Attanasio R. Nonhuman primate IgA: Genetic heterogeneity and interactions with CD89. J Immunol. 2008;180:4816–4824.
151. Nguyen DC, Scinicariello F, Attanasio R. Characterization and allelic polymorphisms of rhesus macaque (Macaca mulatta) IgG Fc receptor genes. Immunogenetics. 2011;63:351–362.
152. Trist HM, Tan PS, Wines BD, et al. Polymorphisms and interspecies differences of the activating and inhibitory FcgammaRII of Macaca nemestrina influence the binding of human IgG subclasses. J Immunol. 2014;192:792–803.
153. Lu CL, Murakowski DK, Bournazos S, et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science. 2016;352:1001–1004.
154. Fouts TR, Tuskan R, Godfrey K, et al. Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. J Virol. 2000;74:11427–11436.
155. Del Prete GQ, Scarlotta M, Newman L, et al. Comparative characterization of transfection- and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies. J Virol. 2013;87:4584–4595.
156. Gomez-Roman VR, Florese RH, Patterson LJ, et al. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Methods. 2006;308:53–67.
157. Guan Y, Pazgier M, Sajadi MM, et al. Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc Natl Acad Sci USA. 2013;110:E69–E78.
158. Rizzuto CD, Wyatt R, Hernandez-Ramos N, et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science. 1998;280:1949–1953.
159. Wyatt R, Kwong PD, Desjardins E, et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 1998;393:705–711.
160. Acharya P, Tolbert WD, Gohain N, et al. Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection. J Virol. 2014;88:12895–12906.
161. Gohain N, Tolbert WD, Acharya P, et al. Cocrystal structures of antibody N60-i3 and antibody JR4 in complex with gp120 define more cluster A epitopes involved in effective antibody-dependent effector function against HIV-1. J Virol. 2015;89:8840–8854.
162. Tolbert WD, Gohain N, Veillette M, et al. Paring down HIV Env: Design and crystal structure of a stabilized inner domain of HIV-1 gp120 displaying a major ADCC target of the A32 region. Structure. 2016;24:697–709.
163. Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis. 2012;54:1615–1617.
164. Forthal DN, Gilbert PB, Landucci G, Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol. 2007;178:6596–6603.
165. Gilbert PB, Peterson ML, Follmann D, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis. 2005;191:666–677.
166. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209–2220.
167. Robb ML, Rerks-Ngarm S, Nitayaphan S, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: A post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis. 2012;12:531–537.
168. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366:1275–1286.
169. Liao HX, Bonsignori M, Alam SM, et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity. 2013;38:176–186.
170. Bonsignori M, Pollara J, Moody MA, et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol. 2012;86:11521–11532.
171. Pollara J, Bonsignori M, Moody MA, et al. HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. J Virol. 2014;88:7715–7726.
172. Rolland M, Edlefsen PT, Larsen BB, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature. 2012;490:417–420.
173. Ferrari G, Pollara J, Kozink D, et al. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol. 2011;85:7029–7036.
174. Ding S, Veillette M, Coutu M, et al. A highly-conserved residue of the HIV-1-gp120 inner domain is important for ADCC responses mediated by anti-cluster A antibodies. J Virol. 2015;90:2127–2134.
175. Gohain N, Tolbert WD, Acharya P, et al. Co-crystal structures of antibody N60-i3 and antibody JR4 in complex with gp120 define more Cluster A epitopes involved in effective antibody-dependent effector function against HIV-1. J Virol. 2015;89:8840–8854.
176. Tomaras GD, Ferrari G, Shen X, et al. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci USA. 2013;110:9019–9024.
177. Van Rompay KK, Berardi CJ, Dillard-Telm S, et al. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J Infect Dis. 1998;177:1247–1259.
178. Forthal DN, Landucci G, Cole KS, Marthas M, Becerra JC, Van Rompay K. Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J Virol. 2006;80:9217–9225.
179. Florese RH, Van Rompay KK, Aldrich K, et al. Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol. 2006;177:4028–4036.
180. Dugast AS, Chan Y, Hoffner M, et al. Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies. PLoS ONE. 2014;9:e97229.
181. Santra S, Tomaras GD, Warrier R, et al. Human non-neutralizing HIV-1 envelope monoclonal antibodies limit the number of founder viruses during SHIV mucosal infection in rhesus macaques. PLoS Pathog. 2015;11:e1005042.
182. Xu JY, Gorny MK, Palker T, Karwowska S, Zolla-Pazner S. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J Virol. 1991;65:4832–4838.
183. Cavacini LA, Emes CL, Wisnewski AV, et al. Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. AIDS Res Hum Retroviruses. 1998;14:1271–1280.
184. Pincus SH, Fang H, Wilkinson RA, Marcotte TK, Robinson JE, Olson WC. In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infection. J Immunol. 2003;170:2236–2241.
185. Lewis GK. Qualitative and quantitative variables that affect the potency of Fc- mediated effector function in vitro and in vivo: Considerations for passive immunization using non-neutralizing antibodies. Curr HIV Res. 2013;11:354–364.
186. Lewis GK, Guan Y, Kamin-Lewis R, Sajadi M, Pazgier M, Devico AL. Epitope target structures of Fc-mediated effector function during HIV-1 acquisition. Curr Opin HIV AIDS. 2014;9:263–270.
187. Lewis GK, Finzi A, Devico AL, Pazgier M. Conformational masking and receptor-dependent unmasking of highly conserved Env epitopes recognized by non-neutralizing antibodies that mediate potent ADCC against HIV-1. Viruses. 2015;18:5115–5132.
188. Moore JP, McCutchan FE, Poon SW, et al. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol. 1994;68:8350–8364.
189. Veillette M, Coutu M, Richard J, et al. The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals. J Virol. 2015;89:545–551.
190. Julien JP, Cupo A, Sok D, et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science. 2013;342:1477–1483.
191. Lyumkis D, Julien JP, de Val N, et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science. 2013;342:1484–1490.
192. Ray K, Mengistu M, Yu L, Lewis GK, Lakowicz JR, DeVico AL. Antigenic properties of the HIV envelope on virions in solution. J Virol. 2014;88:1795–1808.
193. Veillette M, Desormeaux A, Medjahed H, et al. Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. J Virol. 2014;88:2633–2644.
194. Finnegan CM, Berg W, Lewis GK, DeVico AL. Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion. J Virol. 2001;75:11096–11105.
195. Mengistu M, Ray K, Lewis GK, DeVico AL. Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells. PLoS Pathog. 2015;11:e1004772.
196. Richard J, Veillette M, Brassard N, et al. CD4 mimetics sensitize HIV-1-infected cells to ADCC. Proc Natl Acad Sci USA. 2015;112:E2687–E2694.
197. Alsahafi N, Ding S, Richard J, et al. Nef proteins from HIV-1 elite controllers are inefficient at preventing antibody-dependent cellular cytotoxicity. J Virol. 2015;90:2993–3002.
198. Rasheed M, Bettadapura R, Bajaj C. Computational refinement and validation protocol for proteins with large variable regions applied to model HIV Env spike in CD4 and 17b bound state. Structure. 2015;23:1138–1149.
199. Chung AW, Isitman G, Navis M, et al. Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc Natl Acad Sci USA. 2011;108:7505–7510.
200. Kong R, Xu K, Zhou T, et al. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science. 2016;352:828–833.